Cited by

• Mechanotransduction in cardiac hypertrophy and failure.

  Lyon RC, Zanella F, Omens JH, Sheikh F. Lyon RC, et al. Circ Res. 2015 Apr 10;116(8):1462-1476. doi: 10.1161/CIRCRESAHA.116.304937. Circ Res. 2015. PMID: 25858069 Free PMC article. Review.
• Involvement of calcineurin in angiotensin II-induced cardiomyocyte hypertrophy and cardiac fibroblast hyperplasia of rats.

  Fu M, Xu S, Zhang J, Pang Y, Liu N, Su J, Tang C. Fu M, et al. Heart Vessels. 1999;14(6):283-8. doi: 10.1007/BF03257240. Heart Vessels. 1999. PMID: 10901483
• Calcineurin independent development of myocardial hypertrophy in transgenic rats overexpressing the mouse renin gene, TGR(mREN2)27.

  Diedrichs H, Mei C, Frank KF, Boelck B, Schwinger RH. Diedrichs H, et al. J Mol Med (Berl). 2004 Oct;82(10):688-95. doi: 10.1007/s00109-004-0581-9. Epub 2004 Aug 20. J Mol Med (Berl). 2004. PMID: 15322704
• Targeted disruption of NFATc3, but not NFATc4, reveals an intrinsic defect in calcineurin-mediated cardiac hypertrophic growth.

  Wilkins BJ, De Windt LJ, Bueno OF, Braz JC, Glascock BJ, Kimball TF, Molkentin JD. Wilkins BJ, et al. Mol Cell Biol. 2002 Nov;22(21):7603-13. doi: 10.1128/MCB.22.21.7603-7613.2002. Mol Cell Biol. 2002. PMID: 12370307 Free PMC article.
• Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo.

  De Windt LJ, Lim HW, Bueno OF, Liang Q, Delling U, Braz JC, Glascock BJ, Kimball TF, del Monte F, Hajjar RJ, Molkentin JD. De Windt LJ, et al. Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3322-7. doi: 10.1073/pnas.031371998. Proc Natl Acad Sci U S A. 2001. PMID: 11248077 Free PMC article.